Quest Diagnostics (DGX) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.30 per share a year ago. These figures are adjusted for non-recurring items. Quest Diagnostics, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $2.4 billion for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.50%. This compares to year-ago revenues of $2.34 billion. The ...

Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 SECAUCUS, N.J., July 23, 2024 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2024. "We delivered another strong quarter, with base business revenue growth of nearly 4% and total revenue growth of 2.5% as well as continued improvement in productivity and profitability in the base busine ...

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call. This earnings release, including the attached financial tables, is available online in the News ...

BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE:DGX) company, and Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a research collaboration. Lisata will deploy the highly sensitive Haystack MRD™ technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating ce ...

BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a research collaboration. Lisata will deploy the highly sensitive Haystack MRD™ technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating ...

What are the Zacks Style Scores? Value Score Momentum Score How Style Scores Work with the Zacks Rank That's where the Style Scores come in. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.8; value investors should take notice. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Pr ...

Have you been paying attention to shares of Quest Diagnostics (DGX) ? Shares have been on the move with the stock up 5.5% over the past month. The stock hit a new 52-week high of $146.51 in the previous session. Quest Diagnostics has gained 4.9% since the start of the year compared to the 7% move for the Zacks Medical sector and the 8.1% return for the Zacks Medical - Outpatient and Home Healthcare industry. The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings ...

More on the News In the past year, shares of DGX have risen by 3% compared with the industry's growth of 11.5%. Industry Prospects Estimates for DaVita's 2024 earnings per share have remained constant at $9.62 in the past 30 days. Shares of the company have surged 35.4% in the past year compared with the industry's 11.5% growth. Quest Diagnostics (DGX) recently announced a definitive agreement to purchase the select assets of OhioHealth's outreach laboratory services business. The transaction will expand ac ...

Quest Diagnostics (DGX) is set to release second-quarter 2024 results on Jul 23 before the opening bell. Furthermore, Quest Diagnostics' Invigorate initiative is likely to have helped offset the cost headwinds in the quarter under review, enhancing the margin performance. The company may have continued to deploy automation and AI to improve productivity, as well as service levels and quality. Our model forecasts that DGX's cost of services will drop 1.7% sequentially in the second quarter, resulting in a 5% ...

The transaction will broaden access to cost-effective and innovative laboratory services in Ohio. After the acquisition's close, providers and patients will benefit from access to Quest's industry-leading test menu, network of patient service sites throughout the state, broad health plan coverage, and lower out-of-pocket costs for many services. Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our labo ...